[HTML][HTML] Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA. 1 and BA. 2 by convalescent and vaccine serum and monoclonal antibodies

A Wilhelm, M Widera, K Grikscheit, T Toptan… - …, 2022 - thelancet.com
Summary Background In recent months, Omicron variants of SARS-CoV-2 have become
dominant in many regions of the world, and case numbers with Omicron subvariants BA. 1 …

[HTML][HTML] Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA. 1 and BA. 2 by convalescent and vaccine serum and monoclonal antibodies

A Wilhelm, M Widera, K Grikscheit, T Toptan… - eBioMedicine, 2022 - ncbi.nlm.nih.gov
Background In recent months, Omicron variants of SARS-CoV-2 have become dominant in
many regions of the world, and case numbers with Omicron subvariants BA. 1 and BA. 2 …

[PDF][PDF] Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA. 1 and BA. 2 by convalescent and vaccine serum and monoclonal antibodies

A Wilhelm - d-nb.info
Summary Background In recent months, Omicron variants of SARS-CoV-2 have become
dominant in many regions of the world, and case numbers with Omicron subvariants BA. 1 …

[引用][C] Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA. 1 and BA. 2 by convalescent and vaccine serum and monoclonal antibodies

A Wilhelm, M Widera, K Grikscheit, T Toptan, B Schenk… - eBioMedicine, 2022 - cir.nii.ac.jp
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent
and vaccine serum and monoclonal antibodies | CiNii Research CiNii 国立情報学研究所 学術 …

[HTML][HTML] Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA. 1 and BA. 2 by convalescent and vaccine serum and monoclonal antibodies

A Wilhelm, M Widera, K Grikscheit, T Toptan, B Schenk… - eBioMedicine, 2022 - Elsevier
Summary Background In recent months, Omicron variants of SARS-CoV-2 have become
dominant in many regions of the world, and case numbers with Omicron subvariants BA. 1 …

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA. 1 and BA. 2 by convalescent and vaccine serum and monoclonal antibodies

A Wilhelm, M Widera, K Grikscheit… - …, 2022 - publikationen.ub.uni-frankfurt.de
Background: In recent months, Omicron variants of SARS-CoV-2 have become dominant in
many regions of the world, and case numbers with Omicron subvariants BA. 1 and BA. 2 …

[PDF][PDF] Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA. 1 and BA. 2 by convalescent and vaccine serum and monoclonal antibodies

A Wilhelm, M Widera, K Grikscheit, T Toptan, B Schenk… - 2022 - media.ellinikahoaxes.gr
Summary Background In recent months, Omicron variants of SARS-CoV-2 have become
dominant in many regions of the world, and case numbers with Omicron subvariants BA. 1 …

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA. 1 and BA. 2 by convalescent and vaccine serum and monoclonal antibodies.

A Wilhelm, M Widera, K Grikscheit, T Toptan… - Ebiomedicine, 2022 - europepmc.org
Background In recent months, Omicron variants of SARS-CoV-2 have become dominant in
many regions of the world, and case numbers with Omicron subvariants BA. 1 and BA. 2 …

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA. 1 and BA. 2 by convalescent and vaccine serum and monoclonal antibodies

A Wilhelm, M Widera, K Grikscheit, T Toptan… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Background In recent months, Omicron variants of SARS-CoV-2 have become dominant in
many regions of the world, and case numbers with Omicron subvariants BA. 1 and BA. 2 …

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA. 1 and BA. 2 by convalescent and vaccine serum and monoclonal antibodies

A Wilhelm, M Widera, K Grikscheit, T Toptan, B Schenk… - 2022 - publica.fraunhofer.de
Background: In recent months, Omicron variants of SARS-CoV-2 have become dominant in
many regions of the world, and case numbers with Omicron subvariants BA. 1 and BA. 2 …